Table 1.
Baseline characteristics of patients in matched cohorts.
| Variables | VEN + HMA (N = 18) |
7 + 3 (N = 34) |
P value |
|---|---|---|---|
| Age, years, median (range) | 39.5 (17–69) | 41.5 (16–59) | 0.46 |
| Male sex, n (%) | 12 (66.7) | 18 (52.9) | 0.34 |
| ECOG performance status, n (%) | 0.73 | ||
| 0–1 | 13 (72.2) | 23 (67.6) | |
| ≥2 | 5 (27.8) | 11 (32.4) | |
| WBC at diagnosis, ×109/L, n (%) | 0.54 | ||
| > 10 | 9 (50.0) | 14 (41.2) | |
| ≤ 10 | 9 (50.0) | 20 (58.8) | |
| Platelet at diagnosis, ×109/L, n (%) | 0.39 | ||
| > 20 | 10 (55.6) | 23 (67.6) | |
| ≤ 20 | 8 (44.4) | 11 (3.7) | |
| Bone marrow blasts (%), median (range) | 57.3 (35.0–72.8) | 52.0 (32.2–73.0) | 0.72 |
| Karyotype, n (%) | |||
| Sole t (8;21) | 6 (33.3) | 12 (35.3) | 0.75 |
| t (8;21) with ACA | 11 (61.1) | 18 (52.9) | |
| Loss of X/Y | 8 (72.7) | 12 (66.7) | 0.64 |
| del(9q) | 1 (9.1) | 4 (22.2) | |
| Complex karyotypea | 1 (9.1) | 4 (22.2) | |
| del(7q)/−7 | 0 | 1 (5.6) | |
| Trisomy 8 | 0 | 1 (5.6) | |
| UK or failure | 1 (5.6) | 4 (11.8) | |
| Co-mutation, n (%) | |||
| Signal genes | 5 (27.8) | 7 (20.6) | |
| FLT3-ITD/TKD | 3 (16.7) | 4 (11.8) | |
| JAK1/2/3 | 9 (50) | 20 (58.8) | |
| KIT | 3 (16.7) | 6 (17.6) | |
| NRAS/KRAS | 1 (5.6) | 4 (11.8) | |
| Chromatin modification genes | 3 (16.7) | 3 (8.8) | |
| ASXL1/2 | 1 (5.6) | 1 (5.6) | |
| EZH2 | 2 (11.1) | 1 (5.6) | |
| SETD2 | 1 (5.6) | 0 | |
| CREBBP | 2 (11.1) | 2 (5.9) | |
| DNA methylation genes | |||
| DNMT3A | |||
| TET2 | 5 (27.8) | 4 (11.8) | |
| Cohesin genes | 0.17 | ||
| RAD21 | 1 (5.6) | 1 (2.9) | |
| SMC1A/SMC3 | 3 (16.8) | 1 (2.9) | |
| Others | |||
| DHX15 | 2 (11.1) | 1 (2.9) | |
| DNM2 | 1 (11.1) | 2 (5.9) | |
| TP53 | 0 | 0 | |
| ZBTB7A | 1 (5.6) | 2 (5.9) | |
| Immunophenotype, n/N (%) | |||
| CD19 expression | 14/18 (77.8) | 24/34 (70.6) | 0.58 |
| CD56 expression | 11/18 (61.1) | 15/22 (68.2) | 0.64 |
| Extramedullary disease, n (%) | 0.23 | ||
| Yes | 2 (11.1) | 1 (2.9) | |
| No | 16 (88.9) | 33 (97.1) | |
| Allo-HSCT | 0.89 | ||
| Yes | 6 (44.4) | 12 (35.3) | |
| No | 12 (66.6) | 22 (64.7) |
aA complex karyotype was defined as the presence t(8;21) and 2 or more other abnormalities.
Abbreviations: ACA additional cytogenetic abnormalities, Allo-HSCT allogeneic hematopoietic stem cell transplantation, ECOG Eastern Co-operative Oncology Group, UK unknown.